Home › Barton T. Jones

Barton T. Jones

Senior Director, Research Science and Advanced Analytics

A man with a shaved head, light skin, and blue eyes is wearing a light blue collared shirt and a white undershirt. Barton Jones is smiling softly and looking slightly upward. The background is softly blurred.

Barton applies his background in statistics and epidemiology, along with expertise using large health-related databases, to perform data engineering and advanced analytic tasks in support of various projects and products. Barton has been with Inovalon for more than 13 years in various positions consulting with internal and external stakeholders.

Prior to Inovalon, Barton served as a Senior Research Scientist with Avalere Health, where he advised pharmaceutical companies and health plans on a wide range of topics, including studies related to quality measure development, population health, HEOR, comparative effectiveness and safety, and program evaluation. Prior to that he was a Health Data Scientist on the Research, Development, and Analytics team, where he was responsible for quality measure development work with NCQA, analyzing the disparities in the Star-Five Quality Rating system, and disease management program evaluation related to cost, clinical, utilization, and satisfaction outcomes.

Before joining Avalere, Barton was a research intern at the Department of Biostatistics at the University of Michigan, responsible for developing protocols for documenting data checks, assisting with quality control of case report forms, and establishing parameters for code books and data dictionaries.

Barton earned a Master of Biostatistics from the University of Michigan with a cognate in epidemiology and a Bachelor of Mechanical Engineering from Wilkes University with minors in mathematics, physics, and statistics.

Authored Content

Hematology, oncology

Study on Real-World Outcomes with Ibrutinib Dose Reduction

This study examined treatment patterns and outcomes among people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who began ibrutinib and later experienced a treatment-related adverse events.

Social determinants and health equity

Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured Before and After Transition to Medicare Advantage or Traditional Medicare Fee-for-Service

Accepted for presentation at ISPOR 2023. Findings available upon request. Contact us for more information.

Economics

Medicare Advantage vs FFS Enrollment Outcomes Study

This study provides a first look at demographic, clinical, and social risk characteristics of individuals who select MA versus FFS while covered by commercial insurance prior to turning age 65 and compares healthcare outcomes before and after enrolling.

Mental health

Impact of Step Therapy for Chronic Migraine on Pharmacy Costs and Healthcare Resource Utilization

Accepted for presentation at American Headache Society (AHS) 64th Annual Scientific Meeting 2022. Findings available upon request. Contact us for more information.

Oncology

Medical Cost of Care by Line of Treatment (LoT) in Medicare Fee-for-Service (FFS) Beneficiaries with KRAS-mutated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Accepted for presentation at ASCO Quality Care Symposium, 2020. Findings available upon request. Contact us for more information.